Pharmafile Logo

patient expectations

- PMLiVE

Biogen’s tofersen shows promise in rare form of ALS in new data analysis

Mutations in the SOD1 gene are responsible for approximately 2% of global ALS cases

- PMLiVE

Merck to initiate phase 3 HIV-1 clinical programme with a lower dose of islatravir

A phase 2 study evaluating islatravir with Gilead’s lenacapavir will also resume with the lower dose

- PMLiVE

Roche announces launch of HPV self-sampling solution for cervical cancer screening

Around 342,000 die from cervical cancer worldwide, despite it being a preventable disease

- PMLiVE

It’s a Medscape wrap for #EADVCongress

Medscape was on-site at this year’s EADV conference in Milan, with educational activities and a booth to connect with healthcare professionals.At our booth, we spoke with attendees about Medscape and...

Medscape Education

Leveraging the Cloud for Patient-friendly Medical Devices

Robert Kaul, Founder, CEO & President of Cloud DX, explores connected health, remote patient monitoring, telemedicine, and more. He also shares his tips for new entrepreneurs based on his 17...

Impetus Digital

- PMLiVE

AstraZeneca’s Tezspire receives EC approval as severe asthma add-on treatment

Tezspire demonstrated superiority across every primary and key secondary endpoint compared to placebo

- PMLiVE

Merck bags NICE recommendation for renal cell carcinoma adjuvant treatment

Patients will now be able to access immunotherapy at an earlier stage in their treatment pathway

- PMLiVE

Lilly’s Retevmo approved by FDA for RET fusion+ advanced/metastatic solid tumours

Results demonstrated an overall response rate of 44% across multiple tumour types

- PMLiVE

Novo Nordisk’s insulin icodec shows promise as once-weekly type 2 diabetes treatment

Currently, the basal insulin products with the longest duration are injected once daily

- PMLiVE

University of Cambridge launches Early Cancer Institute for complex cancers

It is the first UK institute dedicated to identifying and researching early cancers

- PMLiVE

Medscape Oncology Bids Au Revoir to ESMO for Another Year

ESMO is the leading professional organisation for medical oncology. With more than 25,000 members representing oncology professionals from over 160 countries worldwide, ESMO is the society of reference for oncology education and...

Medscape Education

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links